
|Articles|May 9, 2008
Bevacizumab improves success rate of augmented trabeculectomy for neovascular glaucoma in young diabetic patients
The addition of bevacizumab (Avastin) to trabeculectomy improves the success rate of IOP control, particularly in young diabetic patients with neovascular glaucoma (NVG), according to a study published online, ahead of print, by Eye.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
















































